key: cord-0718363-qo3cfytq
authors: Peng, Yanchun; Mentzer, Alexander J.; Liu, Guihai; Yao, Xuan; Yin, Zixi; Dong, Danning; Dejnirattisai, Wanwisa; Rostron, Timothy; Supasa, Piyada; Liu, Chang; Lopez-Camacho, Cesar; Slon-campos, Jose; Zhao, Yuguang; Stuart, Dave; Paeson, Guido; Grimes, Jonathan; Antson, Fred; Bayfield, Oliver W.; Hawkins, Dorothy EDP.; Ker, De-Sheng; Turtle, Lance; Subramaniam, Krishanthi; Thomson, Paul; Zhang, Ping; Dold, Christina; Ratcliff, Jeremy; Simmonds, Peter; de Silva, Thushan; Sopp, Paul; Wellington, Dannielle; Rajapaksa, Ushani; Chen, Yi-Ling; Salio, Mariolina; Napolitani, Giorgio; Paes, Wayne; Borrow, Persephone; Kessler, Benedikt; Fry, Jeremy W.; Schwabe, Nikolai F.; Semple, Malcolm G; Baillie, Kenneth J.; Moore, Shona; Openshaw, Peter JM; Ansari, Azim; Dunachie, Susanna; Barnes, Ellie; Frater, John; Kerr, Georgina; Goulder, Philip; Lockett, Teresa; Levin, Robert; Cornall, Richard J.; Conlon, Chris; Klenerman, Paul; McMichael, Andrew; Screaton, Gavin; Mongkolsapaya, Juthathip; Knight, Julian C.; Ogg, Graham; Dong, Tao
title: Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients
date: 2020-06-08
journal: bioRxiv
DOI: 10.1101/2020.06.05.134551
sha: 08338d3919d590f618398cc9ea7c7f5064073186
doc_id: 718363
cord_uid: qo3cfytq

COVID-19 is an ongoing global crisis in which the development of effective vaccines and therapeutics will depend critically on understanding the natural immunity to the virus, including the role of SARS-CoV-2-specific T cells. We have conducted a study of 42 patients following recovery from COVID-19, including 28 mild and 14 severe cases, comparing their T cell responses to those of 16 control donors. We assessed the immune memory of T cell responses using IFNγ based assays with overlapping peptides spanning SARS-CoV-2 apart from ORF1. We found the breadth, magnitude and frequency of memory T cell responses from COVID-19 were significantly higher in severe compared to mild COVID-19 cases, and this effect was most marked in response to spike, membrane, and ORF3a proteins. Total and spike-specific T cell responses correlated with the anti-Spike, anti-Receptor Binding Domain (RBD) as well as anti-Nucleoprotein (NP) endpoint antibody titre (p<0.001, <0.001 and =0.002). We identified 39 separate peptides containing CD4+ and/or CD8+ epitopes, which strikingly included six immunodominant epitope clusters targeted by T cells in many donors, including 3 clusters in spike (recognised by 29%, 24%, 18% donors), two in the membrane protein (M, 32%, 47%) and one in the nucleoprotein (Np, 35%). CD8+ responses were further defined for their HLA restriction, including B*4001-restricted T cells showing central memory and effector memory phenotype. In mild cases, higher frequencies of multi-cytokine producing M- and NP-specific CD8+ T cells than spike-specific CD8+ T cells were observed. They furthermore showed a higher ratio of SARS-CoV-2-specific CD8+ to CD4+ T cell responses. Immunodominant epitope clusters and peptides containing T cell epitopes identified in this study will provide critical tools to study the role of virus-specific T cells in control and resolution of SARS-CoV-2 infections. The identification of T cell specificity and functionality associated with milder disease, highlights the potential importance of including non-spike proteins within future COVID-19 vaccine design.

COVID-19 is caused by a recently emerged RNA beta coronavirus, Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2). Whilst the majority of COVID-19 infections are relatively mild, with recovery typically within two to three weeks 1, 2 , a significant number of patients develop severe, often fatal illness, which is postulated to be related to both an overactive immune response and viral induced lung pathology 3, 4 . The role of adaptive T cell immune responses in disease pathogenesis and longer-term protective immunity is currently poorly defined but essential to inform potential therapeutic interventions and enhance vaccine design.

Currently, there are several ongoing vaccine trials, but uncertainties abound and it is unknown whether they will provide long lasting protective immunity. Most vaccines are aimed to induce humoral immunity to the SARS-CoV-2 spike protein, but it is not yet known if this will be sufficient to induce full protective immunity to SARS-CoV-2. A recent study assessed the immune response induced by an adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding the spike protein of SARS-CoV-2 and showed protection from SARS-CoV-2-associated pneumonia in rhesus macaques, but without inducing sterilising immunity 5 . A similar observation was also made by Yu et al when using a DNA vaccine candidate expressing different forms of the SARS-CoV-2 spike (S) protein in a rhesus macaque model 6 . Another study from China in humans assessed safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine, which induced both T cell responses and neutralizing antibody responses to SARS-CoV-2 specifically 7 . Studying natural immunity to the virus, especially the role of SARS-CoV-2-specific T cells is critical to fill the current knowledge gaps for improved vaccine design.

For primary virus infection, it typically takes 7-10 days for adaptive T cell immune responses to be primed and expanded in order to control the virus 8 . This coincides with the typical period of time in which COVID-19 patients to either recover or develop severe illness. There is a median incubation time of 4-7 days in patients before patients developing symptoms and a further 7-10 days before a minority cases progress to severe disease requiring intensive care unit admission and/or mechanical ventilation occurs in a minority of cases 9 . Such a pattern of progression raises the possibility that relative immunosuppression contributes to SARS-CoV-2 viral persistence and COVID-19 mortality, whereas adaptive immune responses are usually protective in the majority of the population.

While T cells are not thought to prevent the establishment of infection, there is good evidence in mice and humans that T cells provide partial protection against many acute viral infections, such as influenza, by promoting viral clearance and reducing the severity of symptoms 1, 10 .

Single cell analysis of bronchoalveolar lavage fluid (BALF) from COVID-19 patients revealed clonal expansions of CD8 + T cells in mild but not severe patients, suggesting that the presence of adaptive T cell responses may be protective in SARS-CoV-2 infection 11 .

Evidence supporting a role for T cells in COVID-19 pathogenesis is currently incomplete and conflicting. Some reports indicate that an overreaction of T cells with high cytotoxicity that causes lung injury 3 rather than a lack of a T cell response; one post-mortem study suggested that direct infection of ACE2-expressing macrophages could lead to activation-induced T cell death (AICD) 12 . In contrast a lack of functional T cells may also contribute to severe disease since lymphocytopenia in COVID-19 patients, especially in older and critically ill cases, may be the cause of functional exhaustion 13 .

To date there have been few studies analysing SARS-CoV-2-specific T cell responses and their role in disease progression 14 . Using HLA-class I and II predicted "Mega" peptide pools, Grifoni et al evaluated CD4 + and CD8 + T cell responses in non-hospitalised convalescent subjects. They found all recovered subjects established CD4 + responses and 70% established CD8 + memory responses to SARS-CoV-2 15 . SARS-CoV-2-specific CD4 + T cell responses were also frequently observed in unexposed subjects in their study, suggesting the possibility of pre-existing cross-reactive immune memory to seasonal coronaviruses.

In the present study, the overall and immunodominant SARS-CoV-2-specific memory T cell response in subjects who had recovered from COVID-19 were evaluated ex vivo using overlapping peptides spanning the full proteome of the SARS-CoV-2, excepting only ORF-1.

Potential epitopes were identified using two-dimensional matrix peptide pools and further evaluated for CD4 + and CD8 + subset involvement. The function of SARS-CoV-2-specific T cells specific for dominant T cell responses were evaluated by intracellular cytokine production profiles, and the HLA restriction of the dominant CD8 + T cell responses was defined using ex vivo and in vitro cultured short-term T cell lines. Broad, and frequently strong, SARS-CoV-2 specific CD4 + and CD8 + T cell responses were seen in the majority of convalescent patients, with a greater proportion of CD8+ T cell responses in mild cases, together with higher frequencies of multi-cytokine producing M-and NP-specific CD8+ T cells.

Patients were recruited from the John Radcliffe Hospital in Oxford, UK, between March and May 2020 by identification of patients hospitalised during the SARS-COV-2 pandemic and recruited into the Sepsis Immunomics and ISARIC Clinical Characterisation Protocols.

Patients were sampled at least 28 days from the start of their symptoms. Unexposed healthy adult donor samples were used from unrelated studies undertaken between 2017-early 2019, and from sero-negative individuals in 2020. Written informed consent was obtained from all patients.

All patients were confirmed to have a test positive for SARS-CoV-2 using reverse transcriptase polymerase chain reaction (RT-PCR) from an upper respiratory tract (nose/throat) swab tested in accredited laboratories. The degree of severity was identified as mild, severe or critical infection according to recommendations from the World Health Organisation. Severe infection was defined as COVID-19 confirmed patients with one of the following conditions: respiratory distress with RR>30/min; blood oxygen saturation<93%; arterial oxygen partial pressure (PaO2) / fraction of inspired O2 (FiO2) <300mmHg; and critical infection was defined as respiratory failure requiring mechanical ventilation or shock; or other organ failures requiring admission to ICU. Since the Severe classification could potentially include individuals spanning a wide spectrum of disease severity spanning patients receiving nasal cannula through to non-invasive ventilation we also calculated the SaO2/FiO2 ratio at the height of patient illness as a quantitative marker of lung damage. This was calculated by dividing the oxygen saturation (as determined using a bedside pulse oximeter) by the fraction of inspired oxygen (21% for ambient air, 24% for nasal cannulae, 28% for simple face masks and 28, 35, 40 or 60% for Venturi face masks or precise measurements for non-invasive or invasive ventilation settings).

A total of 423 15-to 18-mer peptides overlapping by 10 amino acid residues and spanning the full proteome of the SARS-CoV-2 except ORF-1 (253 spike, 29 M, 9 E, 35 ORF3a, 7ORF6, 15 ORF7a, 16 ORF8, 59 NP) were designed using the Los Alamos National Library webbased software PeptGen (http://www.hiv.lanl.gov/content/sequence/PEPTGEN/peptgen.html) and synthesized (purity >75%; Proimmune).

A set of previously defined 27 SARS epitopes 16 were also synthesised ( Table 2), and 19 tetramer and pentamers with those peptides in complex with appropriate Class I and II HLAs were provided by Proimmune.

Pools of Cytomegalovirus (CMV),Epstein-Barr cirus (EBV) and influenza virus specific epitope peptides and The human immunodeficiency viruses (HIV) gag were also used as positive and negative controls.

The overlapping peptides spanning the SARS-CoV-2 were assigned into a 2-dimensional matrix system in which each peptide was represented in 2 different peptide pools. Each peptide pool contains no more than 16 individual peptides. The first dimension of the peptide matrix system was designed so that peptides from different source proteins were separated into different pools. (Supplemental Table 1 ).

IFN-γ ELISpot assays were performed using either freshly isolated or cryopreserved PBMCs as described previously. No significant difference was observed between responses generated by fresh or cryopreserved PBMCs as described previously 17, 18 .

Overlapping peptides were pooled such that the final concentration of each peptide used was 2 μg/mL and then added to 200,000 PBMCs per test for 16-18 h. To quantify antigen-specific responses, mean spots of the control wells were subtracted from the positive wells, and the results expressed as spot forming units (SFU)/10 6 PBMCs. Responses were considered positive if results were at least three times the mean of the negative control wells and >25 SFU/10 6 PBMCs. If negative control wells had >30 SFU/10 6 PBMCs or positive control wells (PHA stimulation) were negative, the results were excluded from further analysis.

MAXISORP immunoplates (442404; NUNC) were coated with 0.125 ug of StrepMAB-Classic (2-1507-001;iba) , blocked with 2% skimmed milk in PBS for one hour and then incubated with 50 ul of 5 ug/ml soluble trimeric Spike 2 ug/ml or 2% skim milk in PBS. After one hour, 50 μL of serial two-fold dilutions of plasma, from 1:50 to 1:51200 in PBS containing 2% skimmed milk were added followed by ALP-conjugated anti-human IgG (A9544; Sigma) at 1:10,000 dilution. The reaction was developed by the addition of PNPP substrate and stopped with NaOH. The absorbance was measured at 405nm. Endpoint titers (EPTs) were defined as reciprocal plasma dilutions that corresponded to two times the average OD values obtained with mock. To determine EPTs to RBD and NP, immunoplates were coated with 0.125ug of Tetra-His antibody (34670; QIAGEN) followed by 2 ug/ml and 5 ug/ml of soluble RBD and NP, respectively.

Confirmed epitope-containing peptides and positive peptide pools were characterized further for their CD4 + and CD8 + subset involvement and cytokine production pattern by intracellular cytokine staining as described previously 19, 20 washed twice with 1× perm/washing buffer and fixed in BD cellfix (BD Bioscience). All antibodies were from Becton Dickinson (BD, Oxford, UK) unless otherwise stated. Cell events were acquired on Fortessa X20 (BD Bioscience) and data files were analyzed using FlowJo software. Data were analyzed using a forward side scatter single cell gate followed by CD8 gating, then tetramer gating within the CD8 + population. These cells were then analyzed for percentage expression of a particular marker using unstained and overall CD8 + populations to determine where to place the gates. Single-color samples were run for compensation, and fluorescence minus one (FMO) control samples were also applied to determine positive and negative populations, as well as channel spillover.

Short-term SARS-CoV-2-specific T cell lines were established as previously described 18 .

Briefly, 3 × 10 6 to 5 × 10 6 PBMCs were pulsed as a pellet for 1 h at 37°C with 10 μM of peptides containing T cell epitope regions and cultured in R10 at 2 × 10 6 cells per well in a 24-well Costar plate. IL-2 was added to a final concentration of 100 U/ml on day 3.

Statistical analysis was performed with IBM SPSS Statistics 25 and figures were made with GraphPad Prism 8. Chi-square tests were used to compare ratio difference between two groups. After testing for normality using Kolmogorov-Smirnov test, Independent-samples t test or Mann-Whitney U test was employed to compare variables between two groups.

Correlations were performed via Spearman's rank correlation coefficient. Statistical significance was set at P<0.05 and all tests were 2-tailed.

Study subjects 42 individuals were recruited following recovery from COVID-19, including 28 mild cases and 14 severe cases. In addition, 19 control individuals sampled in the pre-COVID-19 season were studied in parallel. Supplementary Figure 1 shows the participant characteristics. No significant differences in gender or age were noted between mild and severe groups. The

SaO2/FiO2 ratio in severe cases ranged from 4.3 (where 4.5 would be the estimate for an individual with mild disease breathing ambient air) to 1.6 with the patients with critical disease having an estimate of 0.8 (median in severe group 3.8).

PBMCs were tested for responses to a panel of 423 overlapping peptides spanning all SARS-CoV-2 proteomes except ORF1 using ex vivo IFN-γ ELISpot assays. All overlapping peptides were placed into two 2-dimensional peptide matrix systems as described in Supplementary   Table 1 . 

We have assessed the relationship between spike-specific, and overall T cell responses in association with spike-specific, RBD and NP antibody endpoint titres (EPTs). We found Figure 3D ).

Having identified overall T cell responses to SARS-CoV-2 peptides, the responses detected against positive peptide pools were characterized further for involvement of CD4 + or CD8 + T cell subsets in peptide recognition by evaluating specific intracellular production of IFN-γ and/or TNF-α and/or IL-2 by T cells upon stimulation ( Figure 4A, 4B) . A greater proportion of the T cell responses detected to spike-and M/NP were found to be mediated by CD8+ (rather than CD4+) T cells in those with mild disease compared to those with severe disease ( Figure   4C ).

Multi-cytokine analysis revealed a similar pattern of IFNγ, TNFα and IL-2 production by CD4 + and CD8 + T cells in both mild and severe cases ( Figure 5A ), For 18 individuals tested, both CD4 + and CD8 + antigen-specific-T cells produced least one of these three cytokines and others in combination. Higher proportions of CD4 + T cells were able to produce more than one cytokine than CD8 + T cells ( Figure 5B ). There was no difference in the overall number of multifunctional T cells between the mild group and severe group. Interestingly, CD8 + T cells targeting different virus proteins showed different cytokine profiles, with the M/NP-specific CD8 + T cells having wider functionality than T cells targeting spike protein (p=0.0231, Figure   5B and 5C). Furthermore, the M/NP-specific CD8 + T cells were significantly higher than spikespecific T cells in those with mild disease, but not in those with severe disease. In contrast to observations seen in influenza virus infection 21 , we did not observe significant differences in the cytotoxic potential (as indicated by expression of the degranulation marker CD107a) in patients with mild and severe disease ( Figure 5D ); and we observed very few CD107a + CD4 + T cells overall, suggesting cytotoxic CD4 + T cells might not be a major contributor to virus clearance.

IFNγ ELISpot assays were performed with candidate peptides identified from the 2dimensional matrix analysis in 34 subjects. A total of 39 peptides containing SARS-CoV-2 T cell epitope regions were recognized by COVID-19 recovered subjects, 17 from spike, 10 from NP, 6 from membrane and 7 from ORF proteins. Strikingly, 6 dominant peptides were recognised by more than 18% of subjects tested ( Those dominant responses were further confirmed by both ex-vivo and using cultured shortterm T cell lines. Supplementary Figure 5 illustrates example FACS plots from intracellular cytokine staining (ICS) when short-term T cell lines were stimulated with single peptides containing epitopes. CD4 + T cells elicited strong responses against dominant spike peptides and M peptides, whereas cells targeting two NP dominant peptides were CD8 + T cells. The optimal epitopes recognised within long peptides to which dominant CD8+ responses were detected and their HLA restriction were predicted using the optimal epitope prediction run by IEDB analysis tool (http://tools.iedb.org/mhci). The best predicted epitope sequences identified are shown in Table 2 .

A set of previously defined SARS epitopes 16 with identical sequences to SARS-CoV-2 were also tested by ELISpot assay (Supplementary table 2 N-E-11, which is identical to peptide NP-51, shares the sequence with two other known HLA-A*0201 restricted SARS epitopes (N-E-1 ILLNKHID and N-E-5 ILLNKHIDA). Interestingly, one of the responders to this peptide did not carry the HLA-A*0201 allele (Table 1) , indicating this peptide may contain a different SARS-CoV-2 epitope presented by a different HLA molecule.

Whereas these NP epitopes are targeted by CD8 + T cells, we also detected a CD4 + T cell response targeting SARS spike epitope S-E-19 which spans between the overlapping peptides of S-203 and S-204. This peptide is known to be presented by HLA-DRB1*0401 in SARS infection.

Pre-existing cross-reactive T cell responses to common coronaviruses might play a role in immunity to COVID-19 15 . However, we found the alignment of all epitopes identified here, showed little homology with other common coronaviruses (Supplementary Figure 6 ).

have recovered from COVID-19 stratified for disease severity. We found the breadth and magnitude of the memory T cell responses from convalescent individuals with COVID-19 to be greater in severe compared to mild cases, and this was most markedly observed to spike, M, and ORF3 proteins. M/Np-specific CD8 + T cells were significantly higher frequency than spike-specific CD8 + T cells in those with mild disease. The overall T cell responses as well as spike-specific T cell responses correlated with spike, RBD and NP-specific antibody end point titre. We also identified 39 individual peptides containing CD4 + and/or CD8 + epitopes with 6

immunodominant epitope clusters defined. The memory responses we identified were fully functional and capable of producing IFN-γ TNF-α and IL-2. CD8 + T cells expressed the degranulation marker CD107a consistent with the killing potential of CD8 + cytotoxic T cells. We observed multiple strong dominant CD8 + T cell responses in study subjects specific to the NP protein with dominant epitope clusters within NP (NP-16) detected in 35% study subjects.

In addition, a higher frequency of multi-cytokine producing M/Np-specific than spike-specific CD8 + T cells was observed in subjects who had recovered from mild disease. These findings Taken together, our study has demonstrated strong and broad SARS-CoV-2-specific T cell responses in the majority of subjects who had recovered from COVID-19. Immunodominant epitope clusters and peptides containing T cell epitopes identified in this study will provide critical tools to study the contribution of SARS-CoV-19 specific T cells in protection and immune pathology. Identification of non-spike dominant CD8 + T cell epitopes suggest the potential importance of including of non-spike protein such as NP, M and ORFs into future vaccine designs. Red highlights the overlaps of two adjacent peptides recognised by same subjects; Bold indicates multiple donor responders; Peptides with underline are the 6 immunodominant peptides. na: not available. Optimal epitopes and the corresponding HLA-restriction were predicted by IEDB analysis tool (http://tools.iedb.org/mhci). Red highlights are the predicted optimal epitope sequences and the confirmed HLA restriction. PBMCs were isolated and IFNγ production was detected by ELISpot after incubation with SARS-CoV-2 peptides. A) and B) illustrate the magnitude and the breadth of T cell response against each viral protein between the groups with mild symptoms (n=28) and with severe symptoms (n=14), respectively. SFU spot forming units; Mann-Whitney test was used for the analysis *P<0.05, **P<0.01, ***P<0.001. 

An Overview of Their Replication and Pathogenesis

Coronaviruses post-SARS: update on replication and pathogenesis

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Clinical Characteristics of Coronavirus Disease 2019 in China

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Adaptive immune responses to primary and secondary dengue virus infections

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Cytotoxic T-cell immunity to influenza

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Node

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) Frontiers in Immunology

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals

Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic Live Attenuated Influenza Virus Vaccination

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors

T cell responses to whole SARS coronavirus in humans

Identification of H5N1-specific T-cell responses in a high-risk cohort in vietnam indicates the existence of potential asymptomatic infections

Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China

GS.IG.M Supplementary Table

Oxford Immunology Network Covid-19 response: T cell Immunity Team -additional

Accession